A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer.

N L Berinstein,L Macdonald,M Morse,J J Nemunaitis,G S Chatta,M Karkada,H Kaufman,K Odunsi,R Nigam,M Mansour,M Stanford,G Weir

doi:10.1200/jco.2011.29.15_suppl.e13050

A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer.

N L Berinstein, L Macdonald + Show 10 more

https://doi.org/10.1200/jco.2011.29.15_suppl.e13050

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2011
Citations: 1

#Advanced-stage Prostate Cancer #Advanced-stage Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

e13050 Background: Immunovaccine Inc. (IMV) has developed a novel liposome-in-oil depot vaccine platform called DepoVax (DPX), which increases the potency of peptide-based vaccines. DPX-0907 is a D...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.